For example, a PPARγ activator, rosiglitazone approved by the FDA for the treatment of T2DM, showed effects against steatosis, hepatocellular inflammation, ballooning degeneration, and fibrosis [20]. Here, PPARG is linked to type 2 diabetes mellitus.